Canada's Drug Agency to Decide Mounjaro Coverage Within Weeks
Canada's Drug Agency is expected to announce its coverage recommendation for Eli Lilly's Mounjaro within weeks, a decision that will influence whether provincial drug plans add the tirzepatide injection to their formularies.
Assessment Timeline
The Canadian Drug Agency currently has Mounjaro under assessment for potential inclusion in public drug plans. The timing suggests a decision could come before the end of April 2026, according to recent reports tracking the regulatory process.
Mounjaro contains the active ingredient tirzepatide and is manufactured by Eli Lilly Canada. The drug received Health Canada approval but requires separate coverage assessments from the Canadian Drug Agency for public plan inclusion.
Public Plan Impact
A positive recommendation would likely lead to provincial drug plan coverage across Canada, making Mounjaro accessible through public insurance programs. Currently, patients rely on private insurance or out-of-pocket payments for access to the medication.
The decision comes as provinces manage increasing demand for GLP-1 medications. Recent data indicates approximately 3 million Canadians currently use GLP-1 drugs, creating significant budget pressures for both public and private drug plans.
Market Context
The timing coincides with intense competition in Canada's GLP-1 market. Ozempic and Wegovy from Novo Nordisk already have established market presence, while Health Canada reviews nine generic semaglutide applications.
Recent price reductions by both Novo Nordisk and Eli Lilly have made brand-name GLP-1 medications more competitive ahead of generic competition expected later in 2026.
Provincial Variations
Individual provinces retain final authority over drug plan formularies, even with positive Canadian Drug Agency recommendations. Some provinces have already begun updating their coverage policies in anticipation of increased GLP-1 access.
Alberta Blue Cross recently reported planning for expanded GLP-1 coverage options in 2026, while British Columbia's new national pharmacare program launched in March with coverage for diabetes medications.
Budget Considerations
The Canadian Drug Agency's assessment includes economic evaluations comparing costs and clinical outcomes. Recent estimates suggest Wegovy costs approximately $5,000 annually, while Mounjaro pricing varies by pharmacy and dosage strength.
Employers and public plans are preparing for significant cost increases regardless of coverage decisions, as expanded indications and growing patient populations drive utilization higher across all GLP-1 medications.
Next Steps
The Canadian Drug Agency typically publishes detailed recommendations explaining coverage decisions and any conditions for formulary inclusion. Provincial drug plan administrators then review these recommendations for implementation.
Patients can check current coverage status through their provincial drug plan websites or use insurance coverage checkers to verify benefits under private plans.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
